CASS4

Across TCGA pan-cancer cohorts, CASS4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CASS4 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CASS4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CASS4 expression acts as an unfavorable survival marker.

PDAC, LUAD, and GBM are the cancer types where CASS4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.183	0.888	.001	29	view →
LUAD	OS	Median	All	0.877	1.000	.001	20	view →
GBM	DFS	Tertile	All	0.231	0.459	.014	9	view →
LSCC	DFS	Median	II,III,IV	0.555	0.852	.016	5	view →
HNSC	OS	Tertile	II,III,IV	0.902	1.000	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CASS4–PDAC (OS)

Open the PDAC breakdown →